Author index

Aartsen, E.J., Snethlage, R.A.I., Van Geel, A.N. & Gallee, M.P.W. Squamous cell carcinoma of the vagina in a male pseudohermaphrodite with 5a-reductase deficiency, 283
Abramovici, H. *see* Atad, J.
Acker, B. *see* Hoskins, P.J.
Adams, M. *see* Zablow, A.
Adewole, I.F. *see* Omigbodun, A.O.
Al-Nafussi, A. *see* Rahilly, M.A.
Ali, S., Astley, S.B., Sheldon, T.A., Peel, K.R. & Wells, M. Detection and measurement of DNA adducts in the cervix of smokers and non-smokers, 188
Andersen, J.E. *see* Bertelsen, K.
Anderson, B.L. & Van Der Does, J. Surviving gynecologic cancer and coping with sexual morbidity: an international problem, 225
Arnott, S.J. *see* Sebag-Montefiore, D.J.
Aron, B. *see* Husseinadeh, N.
Astley, S.B. *see* Ali, S.
Atad, J., Weill, S., Ben-David, Y., Hallak, M., Klein, O., Lurie, M. & Abramovici, H. Intraoperative frozen section examination of myometrial invasion depth in patients with endometrial carcinoma, 352
Atkinson, E.N. *see* Freedman, R.S.
Auer, G. *see* Hellstrom, A.-C.
Ayhan, A., Tuncer, R., Tuncer, Z.S., Yuce, K. & Kucukali, T. Correlation between clinical and histopathologic risk factors and lymph node metastases in early endometrial cancer (a multivariate analysis of 183 cases), 306

Baak, J.P. *see* Van Rijswijk, R.E.N.
Baak, J.P.A. *see* Van Diest, P.J.
Baak, J.P.A., Kuik, D.J. & Bezember, P.D. The additional prognostic value of morphometric nuclear arrangement and DNA-ploidy to other morphometric and sterologic features in endometrial hyperplasias, 289
Baehrendtz, H., Einhorn, N., Pettersson, F. & Silfversward, C. Paget's disease of the vulva: the Radiumhemmet series, 1975–1990, 1
Bastert, G. *see* Von Minckwitz, G.
Ben-David, Y. *see* Atad, J.
Berek, J.S. *see* Fowler, J.M.
Berger, C.W. *see* Van Rijswijk, R.E.N.
Bertelsen, K. & Andersen, J.E. Long-term survival and prognostic factors in advanced epithelial ovarian cancer with special emphasis upon the effects of protocol inclusion, 180
Beynon, D.W.G., Lopes, A., Robertson, G., Daras, V. & Monaghan, J.M. Squamous cell carcinoma antigen: pretreatment levels as an indicator of advanced or metastatic disease, 206
Bezember, P.D. *see* Baak, J.P.A.
Blackett, H. & Sharp, F. Conclusions and recommendations from the Helene Harris Memorial Trust Fourth Biennial International Forum on Ovarian Cancer, 135
Blake, P. *see* Ngan, H.Y.S.
Blake, P. *see* Sebag-Montefiore, D.J.
Bouma, J. *see* Duk, J.M.
Bouma, J., Burger, M.P.M., Krans, M., Hollema, H. & Fras, E. Squamous cell carcinoma of the vagina: a report of 32 cases, 395
Bowden, J.M. *see* Freedman, R.S.
Breen, J.L. *see* Zablow, A.
Brown, C. *see* Woolas, R.
Brugghe, J. *see* Van Diest, P.J.
Buck, M. *see* Hunter, R.W.
Buckley, H. *see* Prendiville, J.
Burger, G.T.N. *see* Duk, J.M.
Burger, M.P.M. *see* Bouma, J.

Candlish, W. *see* Rahilly, M.A.
Carlström, K. *see* Möllerström, G.
Cavanagh, D. *see* Gleeson, N.C.
Chapman, P. *see* Evans, B.D.
Cheng, D. *see* Cheung, A.N.Y.
Chenoy, R., Manohar, S., Redman, C.W.E. & Luesley, D.M. Cervical cytologic abnormalities and negative colposcopy: histologic assessment, 348
Cheung, A.N.Y., Hgan, H.Y.S., Cheng, D., Collins, R.J., Gwi, E., Wong, L.C. & Ma, H.K. Clinicopathologic study of 16 cases of primary tubal malignancy, 111
Coates, A. *see* Elliot, P.
Collins, R.J. *see* Cheung, A.N.Y.
Coppleson, M. *see* Elliot, P.
Coppleson, M., Reid, B.L., Skladnev, V.N. & Dalyrmple, J.C. An electronic approach to the detection of pre- cancer and cancer of the uterine cervix: a preliminary evaluation of Polarprobe, 79
Crowther, D. *see* McGown, A.T.
Crowther, D. *see* Prendiville, J.
Curtain, J.P., Morrow, C.P., D'Ablaing, G. & Schlaerth, J.B. Malignant germ cell tumours of the ovary: 20-year report of LAC-USC Women's Hospital, 29

D'Ablaing, G. *see* Curtain, J.P.
Dady, P. *see* Evans, B.D.
Dalyrmple, J.C. *see* Coppleson, M.
Daras, V. *see* Beynon, D.W.G.
Davis, K.P. *see* Lelle, R.J.
De Bruijn, H.W.A. *see* Duk, J.M.
Delcos, L. *see* Freedman, R.S.
Di Re, F., Paladini, D., Fontanelli, R., Feudale, E.A.A. & Raspagliesi, F. Surgical staging for epithelial ovarian tumors of low malignant potential, 310
Duk, J.M., Bouma, J., Burger, G.T.N., Nap, M. & De Bruijn, H.W.A. CA 125 in serum and tumor from patients with uterine sarcoma, 156

Edwards, C.L. *see* Freedman, R.S.
Einhorn, N. *see* Baehrendtz, H.
Einhorn, N. *see* Sjövall, K.

Elliot, P., Green, D., Coates, A., Krieger, M., Russel, P., Coppleson, M., Solomon, J. & Tattersall, M. The efficacy of postoperative vaginal irradiation in preventing vaginal recurrence in endometrial cancer, 84
Evans, B.D., Chapman, P., Dady, P., Forgeson, G., Perez, D., McLeage, M. & Mitchell, P. Carboplantin and chlorambucil combination chemotherapy as treatment for patients with ovarian cancer, 66

Fanning, J., Hilgers, R.D., Richards, P.K. & Hunt, K.D. Carbon dioxide laser vaporization of intestinal metastases of epithelial ovarian cancer, 324
Feichter, G.E. *see* Von Minckwitz, G.
Ferenczy, A., Wright, Jr. T.C. & Richart, R.M. Comparison of CO_2 laser surgery and loop electrosurgical excision/ fulguration procedure (LEEP) for the treatment of vulvar intraepithelial neoplasia (VIN), 22
Feudale, E.A.A. *see* Di Re, F.
Fischer, C. *see* Ngan, H.Y.S.
Fisher, C. *see* Neven, P.
Fontanelli, R. *see* Di Re, F.
Forgeson, G. *see* Evans, B.D.
Fornander, T. *see* Moberger, B.
Fowler, J.M., Nieberg, R.K., Schooler, T.A. & Berek, J.S. Peritoneal adenocarcinoma (serous) of Müllerian type: a subgroup of women presenting with peritoneal carcinomatosis, 43
Fox, B.W. *see* McGown, A.T.
Fras, E. *see* Bouma, J.
Freedman, R.S., Bowden, J.M., Delcos, L., Edwards, C.L., Wallace, S., Atkinson, E.N., Ioannides, C.G., Kasi, L.P., Scott, W. & Patenia, R. Active intralymphatic immunotherapy of uterine cervical carcinoma with viral oncolysate: a pilot study, 101
Fryatt, I. *see* Shepherd, J.H.

Gaarenstroom, K.N., Melkert, P., Walboomers, J.M.M., Van Den Brule, A.J.C., Van Brommel, P.F., Meyer, C.J.L.M., Voorhorst, F.J., Kenemans, P. & Helmerhorst, T.J.M. Human papillomavirus DNA and genotypes: prognostic factors for progression of cervical intraepithelial neoplasia, 73
Gallee, M.P.W. *see* Aartsen, E.J.
Gleeson, N.C., Hoffman, M.S. & Cavanagh, D. Isolated skin bridge metastasis following modified radical vulvectomy and bilateral inguinofemoral lymphadenectomy, 356
Green, D. *see* Elliot, P.
Gregori, C. *see* Zablow, A.
Grudzinskas, J.G. *see* Woolas, R.
Gwi, E. *see* Cheung, A.N.Y.

Hallak, M. *see* Atad, J.
Hammond, I.G. *see* Hunter, R.W.
Hamond, I.G. *see* Williams, K.E.
Harrington, K.J., Lambert, H.E., Kelly, S.A., Lai, P.S. & Price, G.D. Prostaglandin-induced cervical dilatation prior to intracavitary radiotherapy for carcinoma of the cervix: a pilot study, 404
Heep, J. *see* Von Minckwitz, G.
Heinonen, P.K., Isola, J. & Kuoppala, T. Immunohistochemical determination of estrogen and progesterone receptors and DNA flow cytometry in endometrial cancer, 169
Hellström, A.-C. *see* Moberger, B.
Hellström, A.-C., Hue, J., Silfverswärd, C. & Auer, G. DNA-ploidy and mutant p53 overexpression in primary fallopian tube cancer, 408
Hellström, A.-C., Silfverswärd, C., Nilsson, B. & Pettersson, F. Carcinoma of the fallopian tube. A clinical and histopatholgical review. The Radiumhemmet series, 389
Helmerhorst, T.J.M. *see* Gaarenstroom, K.N.
Hendry, W.F. *see* Shepherd, J.H.
Hgan, H.Y.S. *see* Cheung, A.N.Y.
Hilgers, R.D. *see* Fanning, J.
Hoffman, M.S. *see* Gleeson, N.C.
Hollema, H. *see* Bouma, J.
Holm, R. *see* Makar, A.P.
Hoskins, P.J., Swenerton, K.D., Manji, M., Wong, F., O'Reilly, S.E., McMurtrie, E.J., Le, N., Acker, B. & Le Riche, J. 'Moderate risk' ovarian cancer (stage I, grade 2; stage II, grade 1 or 2) treated with cisplatin chemotherapy (single agent or combination) and pelvi-abdominal irradiation, 272
Hudson, C.N. *see* Sebag-Montefiore, D.J.
Hue, J. *see* Hellstrom, A.-C.
Hunt, K.D. *see* Fanning, J.
Hunter, R.W., Williams, K.E., Buck, M. & Hammond, I.G. Metastatic small cell carcinoma of the endometrium: prolonged remission and possible cure following chemotherapy, 127
Husseinadeh, N., Van Aken, M.L. & Aron, B. Ovarian transposition in young patients with invasive cancer receiving radiation therapy, 61

Ioannides, C.G. *see* Freedman, R.S.
Isola, J. *see* Heinonen, P.K.

Jacobs, I. *see* Woolas, R.

Kang, Y.-S. *see* Lee, J.-H.
Kasi, L.P. *see* Freedman, R.S.
Kaufmann, M. *see* Von Minckwitz, G.
Kelly, S.A. *see* Harrington, K.J.
Kenemans, P. *see* Gaarenstroom, K.N.
Kenemans, P. *see* Van Rijswijk, R.E.N.
Kesic, V. *see* Soutter, W.P.
Kim, B.-G. *see* Lee, J.-H.
Klein, O. *see* Atad, J.
Koh, J.-W. *see* Lee, J.-H.
Krans, M. *see* Bouma, J.
Krieger, M. *see* Elliot, P.
Kristensen, G.B. *see* Makar, A.P.
Kucukali, T. *see* Ayhan, A.
Kühn, W. *see* Von Minckwitz, G.
Kuik, D.J. *see* Baak, J.P.A.
Kullander, S. & Rausing, A. Phenotypic characteristics of mononuclear cells in human ovarian tumors—with special reference to cystic and ascitic fluid, 298
Kuoppala, T. *see* Heinonen, P.K.

Lagrelius, A. *see* Möllerström, G.
Lai, P.S. *see* Harrington, K.J.
Lambert, H.E. *see* Harrington, K.J.
Lauder, I.J. *see* Ngan, N.Y.S.
Le, N. *see* Hoskins, P.J.
Le Riche, J. *see* Hoskins, P.J.
Leake, J. *see* Woolas, R.
Lee, E.-D. *see* Lee, J.-H.
Lee, K.-H. *see* Lee, J.-H.
Lee, J.-H., Kang, Y.-S., Koh, J.-W., Park, S.-Y., Kim, B.-G., Lee, E.-D., Lee, K.-H., Park, K.-B. & Seo, Y.-L. p53 gene mutation is rare in human cervical carcinomas with positive HPV sequences, 371
Lelle, R.J., Davis, K.P. & Roberts, J.A. Adenoid cystic carcinoma of the Bartholin's gland: the University of Michigan experience, 145
Lelle, R.J., Morley, G.W. & Peters, W.A. The role of vaginal hysterectomy in the treatment of endometrial carcinoma, 342
Levin, L. *see* Tonkin, K.S.
Lopes, A. *see* Beynon, D.W.G.
Lopes, A.D.B. *see* Ngan, N.Y.S.
Lowe, D.G. *see* Neven, P.
Luesley, D.M. *see* Chenoy, R.
Lurie, M. *see* Atad, J.

Ma, H.K. *see* Cheung, A.N.Y.
Ma, H.K. *see* Ngan, N.Y.S.
McCartney, A.J. *see* Williams, K.E.
McGown, A.T., Murphy, D., Swindell, R., Crowther, D. & Fox, B.W. Correlation of drug resistance-associated parameters in ovarian tumor biopsies, 241
McLeage, M. *see* Evans, B.D.
McLean, C. *see* Sebag-Montefiore, D.J.
McMurtrie, E.J. *see* Hoskins, P.J.
Makar, A.P., Holm, R., Kristensen, G.B., Nesland, J.M. & Tropé, C.G. The expression of c-erbB-2 (HER-2/neu) oncogene in invasive ovarian malignancies, 194
Manji, M. *see* Hoskins, P.J.
Manohar, S. *see* Chenoy, R.
Martin, B.H. *see* Ngan, N.Y.S.
Masotina, A. *see* Neven, P.
Melkert, P. *see* Gaarenstroom, K.N.
Meyer, C.J.L.M. *see* Gaarenstroom, K.N.
Mitchell, P. *see* Evans, B.D.
Moberger, B., Fornander, T. & Hellström, A.-C. DNA-content in endometrial carcinoma of tamoxifen-treated breast cancer patients, 131
Möllerström, G., Lagrelius, A., Carlström, K. & Sjöberg, H.-E. Denser trabecular bone in women with endometrial carcinoma, 161
Monaghan, J.M. *see* Beynon, D.W.G.
Morley, G.W. *see* Lelle, R.J.
Morrow, C.P. *see* Curtain, J.P.
Murad, A.M., Oliveira, M. & Saldanha, T.M. Phase II trial of isotretinoin and interferon alpha-2a in the treatment of advanced recurrent cervical carcinoma, 414
Murphy, D. *see* McGown, A.T.
Murphy, D. *see* Prendiville, J.

Nap, M. *see* Duk, J.M.
Neijt, J.P. *see* Van Diest, P.J.
Nesland, J.M. *see* Makar, A.P.
Neven, P. *see* Shepherd, J.H.
Neven, P., Shepherd, J.H., Masotina, A., Fisher, C. & Lowe, D.G. Management of melanoma of the vulval and vagina: a report of 23 cases presenting in a 10-year period, 379
Ngan, H.Y.S. *see* Shepherd, J.H.
Ngan, H.Y.S., Fischer, C., Blake, P. & Shepherd, J.H. Vaginal sarcoma: the Royal Marsden experience, 337
Ngan, N.Y.S., Lopes, A.D.B., Lauder, I.J., Martin, B.H., Wong, L.C. & Ma, H.K. An evaluation of the prognostic factors in metastatic gestational trophoblastic disease, 36
Nieberg, R.K. *see* Fowler, J.M.
Nilsson, B. *see* Hellström, A.-C.
Nilsson, B. *see* Sjövall, K.

Ogunbiyi, O.A. *see* Scholefield, J.H.
Oliveira, M. *see* Murad, A.M.
Omigbodun, A.O., Thomas, J.O. & Adewole, I.F. Cytological detection of urinary bladder involvement in cervical cancer, 401
Oram, D. *see* Woolas, R.
O'Reilly, S.E. *see* Hoskins, P.J.
Östör, A.G. & Rome, R.M. Micro-invasive squamous cell carcinoma of the cervix: a clinico-pathologic study of 200 cases with long-term follow-up, 257

Paladini, D. *see* Di Re, F.
Paladini, D., Fontanelli, R., Raspagleisi, F. & Ntousias, V. Intestinal operations during surgical procedures for epithelial ovarian cancer, 320
Park, K.-B. *see* Lee, J.-H.
Park, S.-Y. *see* Lee, J.-H.
Patenia, R. *see* Freedman, R.S.
Patsner, B. Is there a role for CT scanning to monitor therapy of optimally debulked patients with advanced ovarian epithelial cancer?, 19
Peel, K.R. *see* Ali, S.
Perez, D. *see* Evans, B.D.
Peters, W.A. *see* Lelle, R.J.
Pettersson, F. *see* Baehrendtz, H.
Pettersson, F. see Hellström, A.-C
Powe, J. *see* Tonkin, K.S.
Prendiville, J., Murphy, D., Renninson, J., Buckley, H. & Crowther, D. Carcinoma of the ovary treated over a 10-year period at the Christie Hospital, 200
Price, G.D. *see* Harrington, K.J.
Prys Davies, A. *see* Woolas, R.

Rahilly, M.A., Candlish, W. & Al-Nafussi, A. Fibrosarcoma arising in an ovarian mucinous tumour: a case report, 211
Raspagliesi, F. *see* Di Re, F.
Rausing, A. *see* Kullander, S.
Redman, C.W.E. *see* Chenoy, R.
Reid, B.L. *see* Coppleson, M.
Renninson, J. *see* Prendiville, J.
Richards, P.K. *see* Fanning, J.
Richart, R.M. *see* Ferenczy, A.
Risberg, B. *see* Sorbe, B.

Roberts, J.A. *see* Lelle, R.J.
Robertson, G. *see* Beynon, D.W.G.
Rogers, K. *see* Scholefield, J.H.
Rome, R.M. *see* Östör, A.G.
Russel, P. *see* Elliot, P.

Saldanha, T.M. *see* Murad, A.M.
Sanfilippo, L.J. *see* Zablow, A.
Schlaerth, J.B. *see* Curtain, J.P.
Schmid, H. *see* Von Minckwitz, G.
Scholefield, J.H., Ogunbiyi, O.A., Smith, J.H.F., Rogers, K. & Sharp, F. Anal colposcopy and the diagnosis of anal intra-epithelial neoplasia in high-risk gynecolgic patients, 119
Schooler, T.A. *see* Fowler, J.M.
Scott, W. *see* Freedman, R.S.
Sebag-Montefiore, D.J., McLean, C., Arnott, S.J., Blake, P., Van Dam, P., Hudson, C.N. & Shepherd, J.H. Treatment of advanced carcinoma of the vulva with chemoradiotherapy—can extenterative surgery be avoided?, 150
Seo, Y.-L. *see* Lee, J.-H.
Sharp, F. *see* Blackett, H.
Sharp, F. *see* Scholefield, J.H.
Sheldon, T.A. *see* Ali, S.
Shepherd, J.H. *see* Neven, P.
Shepherd, J.H. *see* Ngan, H.Y.S.
Shepherd, J.H. *see* Sebag-Montefiore, D.J.
Shepherd, J.H., Ngan, H.Y.S., Neven, P., Fryatt, I., Woodhouse, C.R.J. & Hendry, W.F. Multivariate analysis of factors affecting survival in pelvic exenteration, 361
Silfversward, C. *see* Baehrendtz, H.
Silfversward, C. *see* Hellstrom, A.-C.
Sjöberg, H.-E. *see* Möllerström, G.
Sjövall, K., Nilsson, B. & Einhorn, N. Different types of rupture of the tumor capsule and the impact on survival in early ovarian carcinoma, 333
Skladnev, V.N. *see* Coppleson, M.
Smith, J.H.F. *see* Scholefield, J.H.
Snethlage, R.A.I. *see* Aartsen, E.J.
Solomon, J. *see* Elliot, P.
Sorbe, B., Risberg, B. & Thornwaite, J. Nuclear morphometry and DNA flow cytometry as prognostic methods for endometrial carcinoma, 94
Soutter, W.P. & Kesic, V. Treatment of cervical intraepithelial neoplasia reverses CD4/CD8 lymphocyte abnormalities in peripheral venous blood, 279
Stomberg, K. *see* Varricchio, F.
Swenerton, K.D. *see* Hoskins, P.J.
Swindell, R. *see* McGown, A.T.

Tattersall, M. *see* Elliot, P.
Thomas, J.O. *see* Omigbodun, A.O.
Thornwaite, J. *see* Sorbe, B.
Tognon, G. *see* Van Rijswijk, R.E.N.
Tonkin, K.S., Levin, L. & Powe, J. Neither toxicity nor dose intensity of carboplatin is affected by glomerular filtration rate versus body surface area dose calculation in gynecologic malignancy, 315
Tropé, C.G. *see* Makar, A.P.
Tuncer, R. *see* Ayhan, A.
Tuncer, Z.S. *see* Ayhan, A.

Van Aken, M.L. *see* Husseinadeh, N.
Van Brommel, P.F. *see* Gaarenstroom, K.N.
Van Dam, P. *see* Sebag-Montefiore, D.J.
Van Den Brule, A.J.C. *see* Gaarenstroom, K.N.
Van Den Burg, M.E.L. *see* Van Diest, P.J.
Van Der Does, J. *see* Anderson, B.L.
Van Diest, P.J., Baak, J.P.A., Brugghe, J., Van Den Burg, M.E.L., Van Oosterom, A.T. & Neijt, J.P. Quantitative pathologic features as predictors of long-term survival in patients with advanced ovarian cancer treated with cisplatin, 174
Van Geel, A.N. *see* Aartsen, E.J.
Van Oosterom, A.T. *see* Van Diest, P.J.
Van Rijswijk, R.E.N., Tognon, G., Berger, C.W., Baak, J.P., Kenemans, P. & Vermorken, J.B. The effect of chemotherapy on the different components of advanced carcinosarcomas (malignant mixed mesodermal tumours) of the female genital tract, 52
Varricchio, F. & Stomberg, K. An albumin-like protein is the major secretory protein of ovarian epithelial cells *in vivo* and *in vitro*, 328
Vermorken, J.B. *see* Van Rijswijk, R.E.N.
Von Minckwitz, G., Kühn, W., Kaufmann, M., Feichter, G.E., Heep, J., Schmid, H. & Bastert, G. Prognostic importance of DNA-ploidy and S-phase fraction in endometrial cancer, 250
Voorhorst, F.J. *see* Gaarenstroom, K.N.

Walboomers, J.M.M. *see* Gaarenstroom, K.N.
Wallace, S. *see* Freedman, R.S.
Waters, E.D. *see* Williams, K.E.
Weill, S. *see* Atad, J.
Wells, M. *see* Ali, S.
Williams, K.E. *see* Hunter, R.W.
Williams, K.E., Waters, E.D., Woolas, R.P., Hamond, I.G. & McCartney, A.J. Mixed serous–endometrioid carcinoma of the uterus: pathologic and cytopathologic analysis of a high-risk endometrial carcinoma, 7
Wong, F. *see* Hoskins, P.J.
Wong, L.C. *see* Cheung, A.N.Y.
Wong, L.C. *see* Ngan, N.Y.S.
Woodhouse, C.R.J. *see* Shepherd, J.H.
Woolas, R., Jacobs, I., Prys Davies, A., Leake, J., Brown, C., Grudzinskas, J.G. & Oram, D. What is the true incidence of primary fallopian tube carcinoma?, 384
Woolas, R.P. *see* Williams, K.E.
Wren, B.G., Hormonal therapy following female genital tract cancer, 217
Wright, Jr. T.C. *see* Ferenczy, A.

Yuce, K. *see* Ayhan, A.

Zablow, A., Adams, M., Gregori, C., Breen, J.L. & Sanfilippo, L.J. Stage II adenocarcinoma of the endometrium treated by two standard regimens of combined preoperative irradiation and surgery, 265

Keyword index

abnormal cervical cytology, 348
additional products, 188
adenocarcinoma, 7, 211
adenoid cystic carcinoma, 145
adjuvant chemotherapy, 43
advanced ovarian cancer, 180
albumin, 328
anal, 119
ascites, 298
associated malignancies, 1

Bartholin's gland, 145
bladder, 401
bone density, 161
bowel surgery, 320
breast cancer, 131

CO_2 laser surgery, 22
c-erbB-2, 194
CA, 52, 125, 156, 384
cancer, 272, 395
cancer antigen, 156
carboplatin, 315
carcinoma, 111, 200, 401
carcinoma of the vagina, 389
carcinomatosis, 43
carcinosarcoma, 52, 125, 200
CD4/CD8, 279
cell culture, 328
cellular immunity, 279
cervical cancer, 61, 414
cervical carcinoma, 371, 407
cervical intraepithelial neoplasia, 73
cervical intraepithelial neoplasia (CIN), 279
cervical pre-cancer, 79
cervix, 188, 206, 257, 401
cervix cancer screening, 79
chemotherapy, 52, 127, 150, 174, 200
chemotherapy, 66
colposcopy, 119
combined therapy, 265
complications, 342
cone biopsy, 257
CT scan, 19
cystic fluid, 298
cytometry, 289
cytoreductive surgery, 43

debulking, 19
delay in diagnosis, 389
DNA, 188
DNA analysis, 94
DNA-content, 131
DNA-ploidy, 250
dysgerminoma, 29

electronic detection device, 79
electrosurgery, 22
endometrial cancer, 84, 161, 250, 342
endometrial carcinoma, 94, 131, 169, 265, 352
endometrium, 7, 127, 289
estrogen receptor, 169
expression, 194

fallopian tube, 111, 395
fallopian tube neoplasm, 384
fibrosarcoma, 211
FIGO stage Ia, 257
flow cytometry, 169, 174
follow-up, 73
frozen section, 352

genital tract cancer, 217
glomerular filtration rate, 315
glutathione, 241
growth factors, 217
gynecologic cancer, 225
gynecologic malignancy, 315

histological assessment, 348
HPV, 371
human papilloma-virus, 73
hyperplasia, 289

interferon, 414
intestinal metastases, 324
intracavitary radiotherapy, 407
intraepithelial, 119
intralymphatic immunotherapy, 101

laser, 324
long-term survival, 180
loop cone biopsy, 348
low malignant potential, 310
low stage, 272
lymph node disease, 310
lymph node metastases, 206, 306
lymphocytes, 298

male-pseudohermaphroditism, 279
malignant mixed mesodermal tumor, 52
melanoma, 379
mesoneoplasma, 29
metallothionein, 241
MGTD, 36
micro-invasion, 257
mixed Mullerian tumor, 156
monitoring, 19
morphometry, 174, 289
mucinous cystadenoma, 211
Mullerian, 200
Mullerian duct, 111
multidrug resistance, 241
multivariate analysis, 361
myometrial invasion, 352

negative satisfactory colposcopy, 348
neoplasia, 119
neoplasms staging, 29
nuclear morphometry, 94

oncongene, 194
ovarian, 241
ovarian cancer, 19, 66, 174, 194, 320, 324, 333
ovarian epithelium, 328
ovarian neoplasm, 384
ovarian neoplasms, 29
ovarian transposition, 61
ovarian tumor, 310
ovarian tumors, 298
ovary, 200, 211, 272

p53, 371, 408
Paget's disease, 1
papillary serous carcinoma, 7
pathology, 395
pelvic exenteration, 361
peritoneal adenocarcinoma (serous) of Mullerian type, 43
ploidy, 408
Polarprobe, 79
polymerase chain reaction, 73
predictive value, 250
preoperative, 265
prevention, 84, 389
primary fallopian tube cancer, 408
progesterone receptor, 169
prognosis, 1, 94, 174, 194, 250, 333, 379, 389, 395
prognostic factors, 36, 73, 180, 265
progression, 73, 289
prostaglandin-induced cervical dilatation, 407
psychosocial, 225

quality of life, 225

radical treatment, 1
radiotherapy, 150
retinoic acid, 414
review, 52
risk factors, 342
rupture, 333

S-phase fraction, 169, 250

S-transferase, 241
sarcoma, 200
SCC, 206
screening, 384
serous carcinoma, 7
sex hormones, 217
sexual functioning, 225
sexuality, 225
skin bridge recurrence, 356
small cell carcinoma, 127
smoking, 188
squamous cell, 389
stage II, 265
staging, 379, 401, 408
stereology, 174
surgery, 310, 320
surgical staging, 306
survival, 127, 342
survivor, 225
symptoms, 395

tamoxifen, 131
treatment, 272, 279, 395
triple incisions, 356
tumor grading, 94

univariate & multivariate analysis, 36
urine cytology, 401
uterine cervical cancer, 101
uterine neoplasm, 306
uterine sarcoma, 156
uterus, 7

vagina carcinoma, 279
vaginal, 379
vaginal hysterectomy, 342
vaginal recurrence, 84
vaginal sarcoma, 337
viral oncolysate, 101
vulva, 1, 379
vulvar cancer, 356
vulvar intraepithelial neoplasia, 22
vulvar malignancy, 145
vulvar neoplasm, 150

well-being, 217

young patient, 61



UNITED STATES POSTAL SERVICE

Statement of Ownership, Management, and Circulation
(Required by 39 U.S.C. 3685)

1. Publication Title: Int'l Journal of Gynecological Cancer
2. Publication No.: 1 0 4 8 - 8 9 1 X
3. Filing Date: 7/20/94
4. Issue Frequency: Bimonthly
5. No. of Issues Published Annually: 6
6. Annual Subscription Price: $180
7. Complete Mailing Address of Known Office of Publication (Street, City, County, State, and ZIP+4) (Not Printer): Blackwell Science, Inc. 238 Main Street Cambridge, MA 02142
8. Complete Mailing Address of Headquarters or General Business Office of Publisher (Not Printer): same as #7
9. Full Names and Complete Mailing Addresses of Publisher, Editor, and Managing Editor (Do Not Leave Blank)
Publisher (Name and Complete Mailing Address): Blackwell Science, Inc. 238 Main Street Cambridge, MA 02142
Editor (Name and Complete Mailing Address): Harold Fox, Dept. of Pathological Sciences The Medical School, Stopford Bldg., University of Manchester Manchester, M13 9PT UNITED KINGDOM
Managing Editor (Name and Complete Mailing Address): n/a
10. Owner (If owned by a corporation, its name and address must be stated and also immediately thereafter the names and addresses of stockholders owning or holding 1 percent or more of the total amount of stock. If not owned by a corporation, the names and addresses of the individual owners must be given. If owned by a partnership or other unincorporated firm, its name and address as well as that of each individual must be given. If the publication is published by a nonprofit organization, its name and address must be stated.) (Do Not Leave Blank)

Full Name	Complete Mailing Address
Int'l Society of Gynecological Oncology	Blackwell Science, Inc
c/o Dr. Dennis DePetrillo	238 Main Street
Princess Margaret Hospital	Cambridge, MA 02142
Surgical Oncology 500 Sherbourne Street	
Toronto, Ontario M4X 1K9 CANADA	

11. Known Bondholders, Mortgagees, and Other Security Holders Owning or Holding 1 Percent or More of Total Amount of Bonds, Mortgages, or Other Securities. If none, check here. ☐ None

Full Name	Complete Mailing Address
n/a	n/a

12. For completion by nonprofit organizations authorized to mail at special rates. The purpose, function, and nonprofit status of this organization and the exempt status for federal income tax purposes: (Check one)
☐ Has Not Changed During Preceding 12 Months
☐ Has Changed During Preceding 12 Months (If changed, publisher must submit explanation of change with this statement)

PS Form 3526, October 1994 (See Instructions on Reverse)

13. Publication Name: Int'l Journal of Gynecological Cancer	14. Issue Date for Circulation Data Below: May/Jun. 1994	
15. Extent and Nature of Circulation	Average No. Copies Each Issue During Preceding 12 Months	Actual No. Copies of Single Issue Published Nearest to Filing Date
a. Total No. Copies (Net Press Run)	1,220	1,300
b. Paid and/or Requested Circulation (1) Sales Through Dealers and Carriers, Street Vendors, and Counter Sales (Not Mailed)	0	0
(2) Paid or Requested Mail Subscriptions (Include Advertisers' Proof Copies/Exchange Copies)	815	717
c. Total Paid and/or Requested Circulation (Sum of 15b(1) and 15b(2))	815	717
d. Free Distribution by Mail (Samples, Complimentary, and Other Free)	15	42
e. Free Distribution Outside the Mail (Carriers or Other Means)	0	0
f. Total Free Distribution (Sum of 15d and 15e)	15	42
g. Total Distribution (Sum of 15c and 15f)	830	759
h. Copies Not Distributed (1) Office Use, Leftover, Spoiled	390	541
(2) Return from News Agents	0	0
i. Total (Sum of 15g, 15h(1), and 15h(2))	1,220	1,300
Percent Paid and/or Requested Circulation (15c / 15g x 100)	98%	94%

16. This Statement of Ownership will be printed in the 5/6 issue of this publication. ☐ Check box if not required to publish.
17. Signature and Title of Editor, Publisher, Business Manager, or Owner: James G. Kruger — Date: September 29, 1994

I certify that all information furnished on this form is true and complete. I understand that anyone who furnishes false or misleading information on this form or who omits material or information requested on the form may be subject to criminal sanctions (including fines and imprisonment) and/or civil sanctions (including multiple damages and civil penalties).

Instructions to Publishers

1. Complete and file one copy of this form with your postmaster on or before October 1, annually. Keep a copy of the completed form for your records.
2. Include in items 10 and 11, in cases where the stockholder or security holder is a trustee, the name of the person or corporation for whom the trustee is acting. Also include the names and addresses of individuals who are stockholders who own or hold 1 percent or more of the total amount of bonds, mortgages, or other securities of the publishing corporation. In item 11, if none, check box. Use blank sheets if more space is required.
3. Be sure to furnish all information called for in item 15, regarding circulation. Free circulation must be shown in items 15d, e, and f.
4. If the publication had second-class authorization as a general or requester publication, this Statement of Ownership, Management, and Circulation must be published; it must be printed in any issue in October or the first printed issue after October, if the publication is not published during October.
5. In item 16, indicate date of the issue in which this Statement of Ownership will be printed.
6. Item 17 must be signed.

Failure to file or publish a statement of ownership may lead to suspension of second-class authorization.

PS Form 3526, October 1994 (Reverse)